Mesoporous polydopamine nanoparticles for tumor T1-T2 magnetic resonance imaging

A mesoporous polydopamine and nanoparticle technology, applied in the field of biomedical materials, can solve the problems of not having T1-T2 dual-mode imaging effect and limiting the application of tumor diagnosis and treatment, and achieve good photothermal conversion ability, accurate MRI results, good dispersion effect

CN112759762AActive Publication Date: 2021-05-07SUN YAT SEN UNIV
6 Cites 5 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2021-05-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedical materials, particularly relates to mesoporous polydopamine (MPDA) nanoparticles for tumor T1-T2 magnetic resonance imaging, and aims to prepare mesoporous polydopamine nanoparticles which are internally doped with metal and have a T1-T2 bimodal imaging effect. The manganese-mesoporous polydopamine nanoparticles are prepared by taking dopamine hydrochloride and an Mn precursor as basic raw materials and taking F127 and TMB as templates, and the nanoparticles are polydopamine nanoparticles which are internally doped with metal manganese and have a mesoporous structure, and have tumor microenvironment responsiveness, good photothermal conversion capability and good photothermal stability; the nanoparticles have good biocompatibility, and can be used as a T1 contrast agent and a T2 contrast agent for magnetic resonance imaging of tumors at the same time.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedical materials, and in particular relates to a mesoporous polydopamine nanoparticle used for tumor T1-T2 magnetic resonance imaging. Background technique

[0002] Magnetic resonance imaging (MRI) has attracted extensive attention due to its advantages of high temporal and spatial resolution, no limitation of penetration depth, and no radiation damage. Magnetic resonance contrast agents can enhance MRI signal by reducing the relaxation time of T1 or T2 water protons. T1 is called the longitudinal relaxation time, which is usually used to increase the visualization saturation and suppress the magnetic resonance signal intensity or imaging intensity. Since tissues usually have a long longitudinal relaxation time, T1-weighted images are suitable for observing adipose tissue or anatomical structures. T2 is called the transverse relaxation time, and the proton spin in the lesion usually has a longer rela...

Examples

Embodiment 1

[0051] Example 1 Preparation of manganese-mesoporous polydopamine nanoparticles by doping method before polymerization

[0052] (1) Dissolve 90 mg of dopamine hydrochloride and 3 mg of manganese sulfate hydrate in 3 mL of ultrapure water (the mass ratio of dopamine hydrochloride to manganese sulfate hydrate is 30:1; the mass-volume ratio of manganese sulfate hydrate to ultrapure water is 1 mg:1 mL) , Stir at 180rpm in the dark for 24h to obtain a manganese chelate-dopamine solution;

[0053] (2) the 0.3mL manganese chelation-dopamine solution of 36mg surfactant F127 and step (1) is joined in the mixed solution of 6mL ethanol and 6mL ultrapure water (the mass volume ratio of F127 and manganese chelation-dopamine solution is 120mg: 1mL, the volume ratio of ethanol, ultrapure water and manganese chelation-dopamine solution is 20:20:1), and stirred at 180rpm in the dark for 20min; figure 1 Shown in (1), manganese chelation-dopamine solution, F127 are dispersed in the mixed soluti...

Embodiment 2

[0057] Example 2 Preparation of manganese-mesoporous polydopamine nanoparticles by doping method before polymerization

[0058] (1) 99mg dopamine hydrochloride and 3mg manganese sulfate hydrate are dissolved in 3.75mL ultrapure water (the mass ratio of dopamine hydrochloride and manganese sulfate hydrate is 33:1; the mass volume ratio of manganese sulfate hydrate and ultrapure water is 1mg:1.25 mL), 150rpm avoid light and stir for 26h, obtain manganese chelation-dopamine solution;

[0059] (2) join the manganese chelation-dopamine solution of 30mg surfactant F127 and 0.3mL step (1) in the mixed solution of 4.8mL ethanol and 4.8mL ultrapure water (the mass volume of F127 and manganese chelation-dopamine solution Ratio is 100mg:1mL, the volume ratio of ethanol, ultrapure water and manganese chelation-dopamine solution is 20:20:1.25), 150rpm avoids light and stirs 25min;

[0060] (3) Add 0.3mL 1,3,5-trimethylbenzene (TMB) solution while shaking in a water bath ultrasonic (4kHz) ...

Embodiment 3

[0063] Example 3 Manganese-mesoporous polydopamine nanoparticles prepared by doping before polymerization

[0064] (1) 105mg dopamine hydrochloride and 3mg manganese sulfate hydrate are dissolved in 4.5mg ultrapure water (the mass ratio of dopamine hydrochloride and manganese sulfate hydrate is 35:1; the mass volume ratio of manganese sulfate hydrate and ultrapure water is 1mg:1.5 mL), and stirred at 200rpm in the dark for 22h to obtain manganese chelation-dopamine solution;

[0065] (2) join the 0.3mL manganese chelation-dopamine solution of 45mL surfactant F127 and step (1) in the mixed solution of 4mL ethanol and 4mL ultrapure water (the mass volume ratio of F127 and manganese chelation-dopamine solution is 150mg: 1mL, the volume ratio of ethanol, ultrapure water and manganese chelation-dopamine solution is 20:20:1.5), 150-200rpm dark stirring for 25min;

[0066] (3) Add 0.4mL 1,3,5-trimethylbenzene (TMB) solution while shaking in a water bath ultrasonic (4kHz) at 25°C, an...